CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 250 enrolled
Drug / intervention
VX-150 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03764072
NCT03764072Phase 2Completed
CompareCT.gov

A Phase 2B Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy

Vertex Pharmaceuticals Incorporated·interventional·Posted Dec 4, 2018·Updated Feb 9, 2022

In Brief

A Phase 2 clinical trial evaluating VX-150 and Placebo for Acute Pain. Completed, enrolled 250 participants across 6 sites.

Detailed Summary

This study will evaluate the dose-response relationship and safety of VX-150 in treating acute pain following bunionectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 4, 2018
Enrollment StartDec 12, 2018
Primary CompletionJan 17, 2019
Study CompletionJan 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.6 years ago

Interventions

VX-150drug

Capsules for oral administration.

Placebodrug

Capsules for oral administration.